Cardiogeni (AQSE:CGNI) Forward Dividend Yield %: 0.00% (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cardiogeni Forward Dividend Yield %?

Cardiogeni AQSE:CGNI Forward Dividend Yield % is 0.00% as of Sep. 11, 2026.

As of today (2026-09-11), the Forward Annual Dividend Yield of Cardiogeni is 0.00%.

As of today (2026-09-11), the Trailing Annual Dividend Yield of Cardiogeni is 0.00%.

AQSE:CGNI's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.29
* Ranked among companies with meaningful Forward Dividend Yield % only.

Cardiogeni's Dividends per Share for the six months ended in . 20 was £0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Cardiogeni  (AQSE:CGNI) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Cardiogeni Forward Dividend Yield % Related Terms

AQSE:CGNI vs : Forward Dividend Yield % Comparison

For the Biotechnology subindustry, Cardiogeni's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiogeni Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiogeni's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Cardiogeni's Forward Dividend Yield % falls into.


Cardiogeni Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
Cardiogeni (AQSE:CGNI) has a Forward Dividend Yield % of 0.00% as of Sep. 11, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Cardiogeni and its competitors.
Is Cardiogeni's Forward Dividend Yield % too high?
Cardiogeni's current Forward Dividend Yield % is 0.00%.
How does Cardiogeni's Forward Dividend Yield % compare to ?
Cardiogeni's Forward Dividend Yield % of 0.00% can be compared against companies in the Biotechnology industry. The industry median Forward Dividend Yield % is 1.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.29, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Cardiogeni and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiogeni's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiogeni stock overvalued right now?
Cardiogeni (AQSE:CGNI) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Cardiogeni (AQSE:CGNI), the current Forward Dividend Yield % is 0.00% as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiogeni Business Description

Comparable Companies
Address Celixir House Stratford-Upon-Avon Business & Technology Park, Innovation Way, Stratford upon Avon, GBR, CV37 7GZ
Cardiogeni PLC is engaged in the development and commercialisation of a portfolio of novel cellular medicines for heart failure. The Company focuses on the development and commercialisation of novel cellular medicines targeting early- and mid-stage heart failure. Its strategic priority is to complete a pivotal Phase 2b/3 study and obtain first market approval for its product, CLXR-001, in a suitable jurisdiction, and then establish strategic funding and collaboration agreements to develop and commercialise the product in the US, EU, Japan, and other jurisdictions.